source
- Roche’s enicepatide shows dose-dependent blood sugar and weight loss in Phase 2 diabetes trialRoche reported that its injectable GLP-1/GIP dual agonist enicepatide, acquired through the Carmot Therapeutics purchase, achieved reductions in blood glucose and body weight in a Phase 2 study of…
- Consumer groups call on FDA to strengthen generic drug testing and safety reporting under GDUFA IVConsumer health organizations used a public meeting on the reauthorization of the Generic Drug User Fee Amendments to press the FDA for more resources dedicated to testing generic medicines. The g…